Literature DB >> 4721618

Partial purification and properties of the common inherited forms of adenosine deaminase from human erythrocytes.

W R Osborne, N Spencer.   

Abstract

1. The partial purification of adenosine deaminase, types 1, 2 and 2-1, from human erythrocytes is described. 2. The isoenzyme components characteristic of the three forms of the enzyme were partially resolved by chromatography on DEAE-Sephadex. 3. Gel chromatography of the various forms of the enzyme gave estimates of the molecular weights in the range 30000-35000. 4. Electrophoresis in starch gels containing increasing percentages of starch did not reveal any differences in molecular weight between the genetic variants or their isoenzyme components. 5. Analytical isoelectric-focusing experiments in polyacrylamide gels gave the following pI values for the four isoenzyme components present in type 2-1 erythrocytes: 4.70, 4.83, 4.94 and 5.06. 6. All forms of the enzyme gave K(m) values for adenosine of about 30mum and K(i) values of about 8mum for the competitive inhibitor purine riboside. 7. Reaction rates of the type 1 and 2 enzymes were measured at different temperatures. Both enzymes gave values for the energy of activation for hydrolysis of adenosine of about 33.4kJ/mol (8kcal/mol). 8. Heat inactivation of all forms of the enzyme was markedly dependent on ionic strength, the rate of inactivation increasing with increasing ionic strength. The type 1 and type 2 forms of the enzyme differed significantly in their susceptibility to heat inactivation. From the variation of rates of inactivation with temperature, values were obtained for the energies of activation for the heat inactivation of both enzymes as follows: type 1 enzyme 275.5kJ/mol (65.9kcal/mol) and type 2 enzyme 241.6kJ/mol (57.8kcal/mol.).

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4721618      PMCID: PMC1177676          DOI: 10.1042/bj1330117

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Statistical estimations in enzyme kinetics.

Authors:  G N WILKINSON
Journal:  Biochem J       Date:  1961-08       Impact factor: 3.857

2.  The deaminases of adenosine and adenylic acid in blood and tissues.

Authors:  E J Conway; R Cooke
Journal:  Biochem J       Date:  1939-04       Impact factor: 3.857

3.  Isoelectric focusing of proteins in polyacrylamide gels.

Authors:  O Vesterberg
Journal:  Biochim Biophys Acta       Date:  1972-01-26

4.  Partial purification and properties of the two common inherited forms of human erythrocyte adenylate kinase.

Authors:  C Brownson; N Spencer
Journal:  Biochem J       Date:  1972-12       Impact factor: 3.857

5.  Structural studies on adenosine deaminase from calf intestinal mucosa.

Authors:  J Phelan; F McEvoy; S Rooney; T G Brady
Journal:  Biochim Biophys Acta       Date:  1970-02-17

6.  A comparison of some properties of human red cell acid phosphatase in different phenotypes.

Authors:  J E Luffman; H Harris
Journal:  Ann Hum Genet       Date:  1967-05       Impact factor: 1.670

7.  On the rate-determining step in the action of adenosine deaminase.

Authors:  R Wolfenden
Journal:  Biochemistry       Date:  1969-06       Impact factor: 3.162

8.  Multiple forms of human adenosine deaminase. I. Purification and characterization of two molecular species.

Authors:  H Akedo; H Nishihara; K Shinkai; K Komatsu; S Ishikawa
Journal:  Biochim Biophys Acta       Date:  1972-07-13

9.  Multiple forms of calf serum adenosine deaminase.

Authors:  J G Cory; G Weinbaum; R J Suhadolnik
Journal:  Arch Biochem Biophys       Date:  1967-02       Impact factor: 4.013

10.  Adenosine deaminase from calf spleen. I. Purificiation.

Authors:  N Pfrogner
Journal:  Arch Biochem Biophys       Date:  1967-03       Impact factor: 4.013

View more
  23 in total

1.  Internal initiation of translation in retroviral vectors carrying picornavirus 5' nontranslated regions.

Authors:  M A Adam; N Ramesh; A D Miller; W R Osborne
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

2.  Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency.

Authors:  W P Schrader; B Pollara; H J Meuwissen
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Partial purification and properties of purine nucleoside phosphorylase from rabbit erythrocytes.

Authors:  B Savage; N Spencer
Journal:  Biochem J       Date:  1977-12-01       Impact factor: 3.857

4.  Biochemical and enzymic changes during erythrocyte differentiation. The significance of the final cell division.

Authors:  M J Denton; N Spencer; H R Arnstein
Journal:  Biochem J       Date:  1975-01       Impact factor: 3.857

5.  Purification, properties and assay of D-ribulose 5-phosphate 3-epimerase from human erythrocytes.

Authors:  A Karmali; A F Drake; N Spencer
Journal:  Biochem J       Date:  1983-06-01       Impact factor: 3.857

6.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

7.  Canine cyclic hematopoiesis is associated with abnormal purine and pyrimidine metabolism.

Authors:  W R Osborne; W P Hammond; D C Dale
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

Review 8.  Analysis of normal and mutant forms of human adenosine deaminase - a review.

Authors:  P E Daddona; W N Kelley
Journal:  Mol Cell Biochem       Date:  1980-02-08       Impact factor: 3.396

9.  Design of vectors for efficient expression of human purine nucleoside phosphorylase in skin fibroblasts from enzyme-deficient humans.

Authors:  W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

10.  Purine nucleoside phosphorylase deficiency. Evidence for molecular heterogeneity in two families with enzyme-deficient members.

Authors:  W R Osborne; S H Chen; E R Giblett; W D Biggar; A A Ammann; C R Scott
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.